NeuroTherapeutics Pharma, Inc., or NTP, is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system (CNS) hyper-excitability. The company is working with novel mechanisms that will generate first-in-class therapeutics, thereby changing the standard of care for patients suffering from epilepsy, neuropathic and acute pain, and other disorders of the nervous system.

NTP has identified and patented multiple development candidates that have shown strong efficacy, safety and pharmacologic characteristics. The company is currently preparing an IND (Investigational New Drug) filing for its lead compound, NTP-2014 . NTP has been funded to date via a Series A investment led by Novo A/S and Thomas, McNerney & Partners.

NTP is led by an experienced management team that has significant drug development experience and a strong track record of success within the field of CNS. Team members have filed and had approved multiple new drug applications in the areas of epilepsy, pain, migraine and psychiatry. The management team began working together in 1997, and as a whole has successfully worked together since 2005. They possess a valuable mix of experience and leadership within big pharma, small biopharma, contract research organizations, startup enterprises and banking.